Alzheimer’s disease (AD) research has accelerated the development of biomarkers, enabling the establishment of biological staging that reflects the progression of β-amyloid (Aβ) and tau pathologies in the brain1. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.